Pharmaceuticals

CAHIC

CAHIC released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 1.509 B, actual EPS CNY 0.0237

CAHIC FY2026 Q1 Earnings Release Scheduled for April 30 After-Market BJT

CAHIC released FY2025 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 1.762 B, actual EPS CNY -0.0529

CAHIC released FY2025 annual earnings on April 23 After-Market (BJT), actual revenue CNY 6.205 B (forecast CNY 6.762 B), actual EPS CNY 0.1678 (forecast CNY 0.2133)

CAHIC to Release FY2025 Annual Earnings on April 24 After-Market (BJT), Forecast Revenue CNY 6.762 B, EPS CNY 0.2133

CAHIC released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 1.65 B, actual EPS CNY 0.1405

CAHIC released FY2025 9 Months Earnings on October 27 After-Market (BJT), actual revenue CNY 4.442 B, actual EPS CNY 0.2206

CAHIC to Release FY2025 Q3 Earnings on October 28 After-Market (BJT)

CAHIC released FY2025 Semi-Annual earnings on August 27 Pre-Market (BJT), actual revenue CNY 2.793 B (forecast CNY 3.435 B), actual EPS CNY 0.0801 (forecast CNY 0.25)

CAHIC released FY2025 Q2 earnings on August 27 Pre-Market (BJT), actual revenue CNY 1.534 B, actual EPS CNY 0.0173

CAHIC to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT), Forecast Revenue CNY 3.435 B, EPS CNY 0.25

Zhongmu Shares Receives Clinical Trial Permit for African Swine Fever Subunit Vaccine

China Animal Husbandry Shares Fully Enters Pet Industry

Xu Qing from Southwest Securities Publishes Q1 2025 Report Commentary on Zhongmu Stock

Zhongmu Share 2025 Q1 Financial Report Released

CAHIC released FY2025 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 1.259 B, actual EPS CNY 0.0627

CAHIC FY2025 Q1 Earnings Release Scheduled for April 29, After-Market BJT

Zhongmu Co. Releases 2024 Annual Report with Substantial Net Profit Decrease

CAHIC released FY2024 Q4 earnings on April 11 After-Market (BJT), actual revenue CNY 1.839 B, actual EPS CNY -0.0106

CAHIC released FY2024 annual earnings on April 11 After-Market BJT, actual revenue CNY 6.017 B (forecast CNY 5.352 B), actual EPS CNY 0.0694 (forecast CNY 0.285)

516670

159865

159867

516760

Live cattle futures saw a slight increase of 12 cents in June contracts, while other contracts fell by 30 to 40 cents. Cash trade ranged from $260-265 in the South and $408-415 in the North. Feeder cattle futures dropped by $2 to $2.35. China renewed export licenses for over 400 US beef plants and committed to purchasing $17 billion annually of U.S. agricultural products from 2026 to 2028. Wholesale boxed beef prices rose, with USDA estimating cattle slaughter at 53,500 head last week.

nasdaq

China Merchants CSI Animal Husbandry ETF

Guotai CSI Animal Husbandry ETF

Penghua CSI Animal Husbandry ETF

Ping An CSI Animal Husbandry ETF

Nasdaq

Cattle Slipping Lower on Monday

002714

300498

002157

600195

000735

The Development and Reform Commission of Loudi City, Hunan Province, conducted a survey on pig prices, focusing on breeding, slaughter, and sales segments to assess pig inventory, piglet prices, and feed costs. The survey revealed that the current pig market is oversupplied with low prices, causing financial pressure on breeders. Investigators analyzed the causes, promoted policies to ensure supply and stabilize prices, and urged business entities to regulate their pricing behavior. Moving forward, enhanced monitoring will be implemented, key indicators will be tracked, and data support and decision-making references will be provided for the pig industry

Wallstreetcn

MUYUAN

WENS

ZHENGBANG TECHNOLOGY

New Hope

HKAIT

China Universal CSI Livestock Breeding Industry ETF

Loudi City Development and Reform Commission of Hunan Province Conducts In-depth Research on Pig Prices

600201

A South African Serotype 1 foot-and-mouth disease outbreak has occurred in Xinjiang and Gansu provinces in China, affecting 6,229 cattle with 219 confirmed cases. The virus has spread to pigs. Emergency approval has been granted for vaccines from Zhongnong Weitai and JINYU. Industry analysts believe this outbreak will raise biosafety requirements for the breeding sector, potentially accelerating the scale-up of beef cattle farming and the elimination of backward capacity

JINYU

South African Serotype 1 Foot-and-Mouth Disease Disrupts Livestock Industry Chain

CAHIC: The company has obtained a new veterinary drug registration certificate for the inactivated vaccine against Porcine Seneca Valley Virus

Zhitong

CAHIC announced that the People's Government of Chengguan District, Lanzhou City has decided to requisition the idle assets under its branch and wholly-owned subsidiary, involving state-owned land, buildings, and equipment, with an assessed value of 229 million yuan. The requisition work will be organized and implemented by the Housing and Urban-Rural Development Bureau of Chengguan District, Lanzhou City, and the Yanchang Road Street Office has been entrusted to be responsible for the compensation and resettlement work

Idle assets under the branches and subsidiaries of CAHIC will be confiscated

According to the Zhitong Finance APP, CAHIC disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 2.793 billion yuan, a year-on-year increase of 12.63%; net profit attributable to the parent company was 81.76 million yuan, a year-on-year increase of 30.19%; net profit excluding non-recurring gains and losses was 81.67 million yuan, a year-on-year increase of 39.35%; basic earnings per share were 0.0801 yuan

CAHIC released its semi-annual performance report, with a net profit attributable to the parent company of 81.76 million yuan, a year-on-year increase of 30.19%

According to the Zhitong Finance APP, CAHIC announced that it has recently received the clinical trial approval for the African Swine Fever subunit vaccine issued by the Ministry of Agriculture and Rural Affairs (Approval No.: 2025058). The African Swine Fever subunit vaccine is used to prevent African Swine Fever virus infection. The company collaborated with research institutions to develop this vaccine in 2023. As of now, the total research and development investment for this product is approximately RMB 46.2446 million

CAHIC has obtained the clinical trial approval for the African swine fever subunit vaccine

300119

688136

The animal vaccine sector continues to rise, with JINYU hitting the daily limit, and RINGPU, SDKX, HKAIT, and CAHIC following suit

RINGPU

SDKX

The animal vaccine sector continues to rise, with JINYU hitting the daily limit

CAHIC released its 2024 annual report, with operating revenue of 6.017 billion yuan, a year-on-year increase of 11.30%. The net profit attributable to shareholders was 70.8844 million yuan, a year-on-year decrease of 82.41%. The net profit after deducting non-recurring gains and losses was 62.1379 million yuan, a year-on-year decrease of 77.72%. The basic earnings per share were 0.0694 yuan, and it plans to distribute a cash dividend of 0.23 yuan for every 10 shares to all shareholders. The decline in net profit was mainly due to a decrease in gross profit and investment income

CAHIC released its 2024 annual performance, with a net profit attributable to the parent company of 70.8844 million yuan, a decrease of 82.41%

CAHIC released its performance forecast for 2024, expecting a net profit of between 62.51 million yuan and 88.03 million yuan, a year-on-year decrease of 78.16% to 84.49%. The net profit after deducting non-recurring gains and losses is expected to be between 57.79 million yuan and 83.31 million yuan, a year-on-year decrease of 70.12% to 79.28%

CAHIC issued a profit warning, expecting a net profit of 62.51 million to 88.03 million yuan for the year 2024, a year-on-year decrease of 78.16% to 84.49%

CAHIC(600195.SH)